The Transgenic &Targeting Core Facility is the sole service generating genetically modified mice for the Case CCC and the Cleveland Biomedical community. The services offered are the generation of transgenic and knockout mice, rederivations, in vitro fertilization, generation of chimeric mice, and the design and construction of DNA vectors. The Core began to offer sperm cryopreservation for inbred strains in 2009. The Core provides consultation on scientific, technical and practical matters of mouse genetics. It is the only Transgenic facility in the Cleveland area, and serves investigators at CWRU, University Hospitals, Cleveland Clinic, the VA Hospital, MetroHealth Medical Center, and Kent State University. The facility operates on a fee-for-service basis, and provides consultation with all services. The facility supports the Case CCC mission through the generation of mouse models of cancer, and tools and materials for investigation of basic science questions. The Core is formally accessible by all members of the Case CCC. The Transgenic &Targeting Core Facility is competitive with transgenic cores at other academic institutions in success rates, turnaround, and pricing. As a local service, it has advantages for cancer investigators by direct access to consultation and training, better pricing of services, and control of mouse pathogens. The Core has helped a number of labs with minimal or no experience transition into mouse genetic research programs. In the last funding period the Core has assisted Cancer Center members in: generating mice that model human mutations leading to cancer;identifying cancer susceptibility loci;generating mice for in vivo imaging of tumors;and investigating the basic biology of genes implicated in cancer. Since 2007, Cancer Center members have published 23 peer-reviewed papers with transgenic or knockout mice generated by the facility, and since 2004, transgenic or gene targeted mice created by the Core have been featured in 36 publications by Case CCC members.
The Case Comprehensive Cancer Center is Northeast Ohio's only NCI designated comprehensive cancer center providing bench-to-bedside medical research involving partnerships between basic, clinical and population scientists to speed translation of laboratory discoveries into new prevention/intervention and cancer treatments.
|Zhao, S; Sedwick, D; Wang, Z (2015) Genetic alterations of protein tyrosine phosphatases in human cancers. Oncogene 34:3885-94|
|Dermawan, Josephine Kam Tai; Gurova, Katerina; Pink, John et al. (2014) Quinacrine overcomes resistance to erlotinib by inhibiting FACT, NF-?B, and cell-cycle progression in non-small cell lung cancer. Mol Cancer Ther 13:2203-14|
|Brubaker, Douglas; Difeo, Analisa; Chen, Yanwen et al. (2014) Drug Intervention Response Predictions with PARADIGM (DIRPP) identifies drug resistant cancer cell lines and pathway mechanisms of resistance. Pac Symp Biocomput :125-35|
|Yori, Jennifer L; Lozada, Kristen L; Seachrist, Darcie D et al. (2014) Combined SFK/mTOR inhibition prevents rapamycin-induced feedback activation of AKT and elicits efficient tumor regression. Cancer Res 74:4762-71|
|Dabir, Snehal; Kluge, Amy; McColl, Karen et al. (2014) PIAS3 activates the intrinsic apoptotic pathway in non-small cell lung cancer cells independent of p53 status. Int J Cancer 134:1045-54|
|Zapanta Rinonos, Serendipity; Rai, Urvashi; Vereb, Sydney et al. (2014) Sequential logic of polarity determination during the haploid-to-diploid transition in Saccharomyces cerevisiae. Eukaryot Cell 13:1393-402|
|Sizemore, Gina M; Sizemore, Steven T; Seachrist, Darcie D et al. (2014) GABA(A) receptor pi (GABRP) stimulates basal-like breast cancer cell migration through activation of extracellular-regulated kinase 1/2 (ERK1/2). J Biol Chem 289:24102-13|
|Sossey-Alaoui, Khalid; Pluskota, Elzbieta; Davuluri, Gangarao et al. (2014) Kindlin-3 enhances breast cancer progression and metastasis by activating Twist-mediated angiogenesis. FASEB J 28:2260-71|
|Dotan, Efrat; Devarajan, Karthik; D'Silva, A James et al. (2014) Patterns of use and tolerance of anti-epidermal growth factor receptor antibodies in older adults with metastatic colorectal cancer. Clin Colorectal Cancer 13:192-8|
|Arachiche, Amal; de la Fuente, María; Nieman, Marvin T (2014) Platelet specific promoters are insufficient to express protease activated receptor 1 (PAR1) transgene in mouse platelets. PLoS One 9:e97724|
Showing the most recent 10 out of 975 publications